Close menu




October 14th, 2021 | 11:27 CEST

BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!

  • Biotechnology
Photo credits: pixabay.com

Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    BioNTech - Correction in the thin mountain air

    The papers of BioNTech are still in correction mode. The discount from the top is now 47%. What happened? Not much, really, except that the remaining willingness to vaccinate in most Western nations has now fallen very far, meaning that the people who wanted a vaccination have already received it. However, 50% of all vaccination centers are closed, and the previously strong media attention is declining. As a result, the vaccine is waiting on the shelves for new buyers who are no longer widely available.

    This leads to recalculations about the remaining sales potential for the established manufacturers. BioNTech is the absolute top dog in Germany with a market share of over 80%. Therefore, the coming weeks remain exciting for the Company, as the flu season has probably started according to the calendar. A cancer congress provides further hope in mid-November, at which the Mainz-based Company plans to present some new research data. Most recently, however, Merck & Co's trial success with a Corona drug has put pressure on the vaccine squad.

    Analysts at US investment bank Goldman Sachs have again looked at the German biotech stock and reaffirmed their positive assessment. Although the price target of USD 433 is a full 80% above the current price, the vote is only "Neutral". The analysts believe that BioNTech's shares have already priced in the fact that 45% of those vaccinated will receive a booster in the fall and that sales will be split between Pfizer/BioNTech and Moderna. We will see how the pandemic winter plays out. The BioNTech share is not overpriced now either, with a P/E of 12. Buy the dips!

    Cardiol Therapeutics - With measurable steps forward

    Cardiol Therapeutics Inc.'s portfolio currently consists of therapies that are in clinical trials and in development, under the brand name CardiolRx™.

    Currently, CardiolRx is a highly purified and concentrated oral cannabidiol formulation that has recently received IND (Investigational New Drug) application clearance from the FDA for a Phase II clinical trial in acute myocarditis. The formulation will be clinically tested on 100 patients in the U.S., Canada and Europe, and the IND approval alone is a major milestone for the still young company. The treatment of inflammatory heart disease has become a major focus of the pharmaceutical industry, particularly due to the COVID pandemic. Cardiol has already made considerable progress in this area.

    The results of the Phase II trial are expected to be released to the public in the first quarter of 2023, and the Company will certainly provide some research data before then. Already, however, Cardiol Therapeutics has made a name for itself as a specialist in innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). There are likely to be some surprises in the pipeline here.

    The Nasdaq listing contributed to a high level of attention with the CRDL share in recent months, causing the price to explode to over CAD 6 on the Canadian home exchange. Currently, the stock is correcting somewhat and is trading between CAD 4.00 and 4.40. The share is very liquid and offers the speculative investor favorable buying and selling opportunities again and again. With a successful Phase II trial, however, the share price will move into other dimensions. The analysts of GBC Research already assign a price target of CAD 17.49. Thus, a good entry opportunity is currently offered.

    Please learn first-hand about the Company's potential through CEO David Elsley's presentation today at the investor conference "IIF - International Investment Forum" at 3pm.

    CureVac - Withdrawal from the EMA approval process

    After CureVac was considered an mRNA pioneer at the beginning of the pandemic, the manufacturer from Tübingen recently flopped with its Covid-19 vaccine. However, on closer inspection, the problems were already apparent at the start: While numerous competitors had long since brought their vaccine to market, CureVac was still collecting data.

    CureVac is now withdrawing its vaccine from the EMA approval process. For the Tübingen-based biotech Company, this is a bitter but ultimately strategically correct decision. Given the disappointing study data, the CureVac vaccine would have had little chance of commercialization anyway, even if it had been approved. There are already four approved competitor products on the market, all of which are more effective.

    The realignment now allows the Tübingen-based Company to devote more of its still comparatively ample resources to potential successor products, improving its technology and other projects. The starting point for the next attempt may be better in that the Company has an experienced partner on board in the form of pharmaceutical giant GlaxoSmithKline, which is now likely to take over the direction of further development. It may also be appropriate to diversify into other areas of research. But even this offers no guarantee of success, especially since the British group has been unable to demonstrate any measurable success in drug development in recent years.

    For these reasons, the risks in the CureVac share continue to be assessed as considerable. In any case, shareholders will still need some patience, and it does not help that the share price has already fallen a full 72% from its high. The market capitalization of just under EUR 7 billion is still lush. In retrospect, we were right to be cautious about CureVac.


    Investing in bio-pharma stocks is currently characterized by high volatility. Nevertheless, the "vaccination" theme may revive in the winter. BioNTech and CureVac are good examples of the ups and downs in a highly competitive industry. On the other hand, Cardiol Therapeutics is operating in a therapeutic field that has outstanding long-term potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST

    BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?

    • Biotechnology
    • Monkeypox

    The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.

    Read

    Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST

    Booster for the BioNTech share: BASF and Defense Metals with momentum?

    • RareEarths
    • Biotechnology

    The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.

    Read

    Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

    Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

    • Biotechnology
    • Covid19

    For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?

    Read